Back to List View Graph View

Fibrosis

Fibrosis is a pathological process in which persistent tissue injury, inflammation, or cellular stress promotes activation of fibroblasts and excessive deposition of extracellular matrix components, particularly collagen.

Where the papers sit

11 papers from the last 6 months study fibrosis directly · updated from PubMed 8 Nov 2026

Study type 0 clinical trials · 2 observational · 1 human data · 3 preclinical · 5 unclassified

Themes 3 themes

  • MASLD Fibrosis Assessment

    MASLD care is moving toward integrated, non-invasive fibrosis risk stratification in people with diabetes. Magnetic resonance elastography, Fibrosis-4, LITMUS testing, and deep-learning elastography aim to replace or reduce biopsy dependence. Pharmacist-led screening embeds risk assessment within diabetes care. Luseogliflozin added to semaglutide extends this approach from staging toward combined metabolic and liver-directed treatment.

    5 papers · 45.5%

  • Inflammatory Fibrosis Pathways

    PPARα/CCL2 signaling links lipid metabolism to inflammatory fibrosis in MASH. Lipidated amino acid deficiency and altered fatty acid oxidation emerge as targets for restoring this axis. In thyroid eye disease, digoxin acts through HIF-1α inhibition to reduce inflammation and fibrosis. The work is moving toward pathway-specific antifibrotic interventions rather than nonspecific suppression.

    2 papers · 18.2%

  • Others — Fibrosis and Cellular Therapeutics

    Macrophage endotoxin tolerance, engineered MSCs, NKG2D-CAR T cells, and trichrome-based deep learning appear together without a unified biological question. MASH studies focus on AOAH-mediated LPS inactivation and quantitative pathology. Separate work targets integrated stress response in fibrosis or NKG2D-CAR T activity in breast cancer. The cluster therefore has no defensible shared therapeutic trajectory.

    4 papers · 36.4%

Papers

The 11 papers from the last 6 months that study fibrosis directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

MASLD Fibrosis Assessment (5)
  1. Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study. Lancet (London, England) · 29 Oct 2026 PMID 42956772
  2. Embedding metabolic dysfunction-associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808546
  3. Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42605535
  4. Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
  5. A combi-elasto ultrasound based deep learning model on liver fibrosis staging for suspected MASLD/MASH patients. BMC medical imaging · 18 Jul 2026 PMID 42471585
Inflammatory Fibrosis Pathways (2)
  1. Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
  2. Digoxin inhibits HIF-1α to attenuate inflammation and fibrosis in thyroid eye disease. Biochemical and biophysical research communications · 24 Jul 2026 PMID 42497831
Others — Fibrosis and Cellular Therapeutics (4)
  1. Trichrome-based deep learning for quantitative assessment of steatosis, hepatocellular ballooning, and fibrosis in metabolic dysfunction-associated steatohepatitis. Virchows Archiv : an international journal of pathology · 6 Nov 2026 PMID 42995264
  2. AOAH-mediated LPS inactivation limits macrophage endotoxin tolerance and promotes inflammation and fibrosis in MASH. Cellular and molecular gastroenterology and hepatology · 29 Aug 2026 PMID 42668090
  3. Engineered mesenchymal stem cells regulate integrated stress response for fibrosis therapy. Med (New York, N.Y.) · 12 Aug 2026 PMID 42586072
  4. All-trans retinoic acid and lansoprazole potentiated NKG2D-CAR T for breast cancer treatment. International immunopharmacology · 20 May 2026 PMID 42161056

By study type

Observational studies and case reports (2)
  1. Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study. Lancet (London, England) · 29 Oct 2026 PMID 42956772
  2. Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
Human data, design not indexed (1)
  1. Embedding metabolic dysfunction-associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808546
Preclinical: animal, cell and lab studies (3)
  1. Engineered mesenchymal stem cells regulate integrated stress response for fibrosis therapy. Med (New York, N.Y.) · 12 Aug 2026 PMID 42586072
  2. Digoxin inhibits HIF-1α to attenuate inflammation and fibrosis in thyroid eye disease. Biochemical and biophysical research communications · 24 Jul 2026 PMID 42497831
  3. All-trans retinoic acid and lansoprazole potentiated NKG2D-CAR T for breast cancer treatment. International immunopharmacology · 20 May 2026 PMID 42161056
Unclassified: not yet indexed with MeSH (5)
  1. Trichrome-based deep learning for quantitative assessment of steatosis, hepatocellular ballooning, and fibrosis in metabolic dysfunction-associated steatohepatitis. Virchows Archiv : an international journal of pathology · 6 Nov 2026 PMID 42995264
  2. Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
  3. AOAH-mediated LPS inactivation limits macrophage endotoxin tolerance and promotes inflammation and fibrosis in MASH. Cellular and molecular gastroenterology and hepatology · 29 Aug 2026 PMID 42668090
  4. Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42605535
  5. A combi-elasto ultrasound based deep learning model on liver fibrosis staging for suspected MASLD/MASH patients. BMC medical imaging · 18 Jul 2026 PMID 42471585